Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas (original) (raw)
Ammirati M, , Galicich JH, & Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614, 1987 Ammirati M, Galicich JH, Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. **Neurosurgery 21:**607–614, 1987
PubMed Ammirati M, Galicich JH, Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607– 614, 1987 Ammirati M, Galicich JH, Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614, 1987 10.1227/00006123-198711000-00001 )| false
Brem H: Controlled-release polymer systems for drug delivery to the brain. Polymer Preprints 31:229, 1990 Brem H: Controlled-release polymer systems for drug delivery to the brain. **Polymer Preprints 31:**229, 1990 (Abstract)
PubMed Brem H: Controlled-release polymer systems for drug delivery to the brain. Polymer Preprints 31: 229, 1990 (Abstract) Brem H: Controlled-release polymer systems for drug delivery to the brain. Polymer Preprints 31:229, 1990 (Abstract) )| false
Brem H, , Kader A, & Epstein JI, et al: Controlled delivery of 1,3,-bis(2-chloroethyl)-1-nitrosourea from ethylenevinyl acetate copolymer. Select Cancer Ther 5:55–65, 1989 Brem H, Kader A, Epstein JI, et al: Controlled delivery of 1,3,-bis(2-chloroethyl)-1-nitrosourea from ethylenevinyl acetate copolymer. **Select Cancer Ther 5:**55–65, 1989
PubMed Brem H, Kader A, Epstein JI, et al: Controlled delivery of 1,3,-bis(2-chloroethyl)-1-nitrosourea from ethylenevinyl acetate copolymer. Select Cancer Ther 5: 55– 65, 1989 Brem H, Kader A, Epstein JI, et al: Controlled delivery of 1,3,-bis(2-chloroethyl)-1-nitrosourea from ethylenevinyl acetate copolymer. Select Cancer Ther 5:55–65, 1989 )| false
Brem H, , Tamargo RJ, & Olivi A: Delivery of drugs to the brain by use of a sustained release polymer system, in Salem H (ed): New Technologies and Concepts for Reducing Drug Toxication. Caldwell, NJ: Telford Press, 1990 Brem H, Tamargo RJ, Olivi A: Delivery of drugs to the brain by use of a sustained release polymer system, in Salem H (ed): New Technologies and Concepts for Reducing Drug Toxication. Caldwell, NJ: Telford Press, 1990 (In press)
PubMed Brem H, Tamargo RJ, Olivi A: Delivery of drugs to the brain by use of a sustained release polymer system, in Salem H (ed): New Technologies and Concepts for Reducing Drug Toxication. Caldwell, NJ: Telford Press, 1990 (In press) Brem H, Tamargo RJ, Olivi A: Delivery of drugs to the brain by use of a sustained release polymer system, in Salem H (ed): New Technologies and Concepts for Reducing Drug Toxication. Caldwell, NJ: Telford Press, 1990 (In press) )| false
Chasin M, , Domb A, & Ron E, et al: Polyanhydrides as drug delivery systems, in Langer R, & Chasin M (eds): Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp 43–70 Chasin M, Domb A, Ron E, et al: Polyanhydrides as drug delivery systems, in Langer R, Chasin M (eds): Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp 43–70
PubMed Chasin M, Domb A, Ron E, et al: Polyanhydrides as drug delivery systems, in Langer R, Chasin M (eds): Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp 43– 70 Chasin M, Domb A, Ron E, et al: Polyanhydrides as drug delivery systems, in Langer R, Chasin M (eds): Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp 43–70 )| false
Chasin M, , Lewis D, & Langer R: Polyanhydrides for controlled drug delivery. Biopharm Manufact 1:33–46, 1988 Chasin M, Lewis D, Langer R: Polyanhydrides for controlled drug delivery. **Biopharm Manufact 1:**33–46, 1988
PubMed Chasin M, Lewis D, Langer R: Polyanhydrides for controlled drug delivery. Biopharm Manufact 1: 33– 46, 1988 Chasin M, Lewis D, Langer R: Polyanhydrides for controlled drug delivery. Biopharm Manufact 1:33–46, 1988 )| false
Domb A, & Langer R: I. Preparation of high molecular weight polyanhydride. J Polymer Sci 25:3373–3386, 1987 Domb A, Langer R: I. Preparation of high molecular weight polyanhydride. **J Polymer Sci 25:**3373–3386, 1987
PubMed Domb A, Langer R: I. Preparation of high molecular weight polyanhydride. J Polymer Sci 25: 3373– 3386, 1987 Domb A, Langer R: I. Preparation of high molecular weight polyanhydride. J Polymer Sci 25:3373–3386, 1987 )| false
Domb A, , Ron E, & Langer R: Polyanhydride II: one step polymerization using phosgene or diphosgene as coupling agents. Macromolecules 12:1925–1929, 1988 Domb A, Ron E, Langer R: Polyanhydride II: one step polymerization using phosgene or diphosgene as coupling agents. **Macromolecules 12:**1925–1929, 1988
PubMed Domb A, Ron E, Langer R: Polyanhydride II: one step polymerization using phosgene or diphosgene as coupling agents. Macromolecules 12: 1925– 1929, 1988 Domb A, Ron E, Langer R: Polyanhydride II: one step polymerization using phosgene or diphosgene as coupling agents. Macromolecules 12:1925–1929, 1988 )| false
Grossman SA, , Rienhard CS, & Brem H, et al: The intracerebral delivery of BCNU with surgically implanted bioerodible polymers: a quantitative autoradiographic study. Proc Am Soc Clin Oncol 7:84, 1988 Grossman SA, Rienhard CS, Brem H, et al: The intracerebral delivery of BCNU with surgically implanted bioerodible polymers: a quantitative autoradiographic study. **Proc Am Soc Clin Oncol 7:**84, 1988 (Abstract)
PubMed Grossman SA, Rienhard CS, Brem H, et al: The intracerebral delivery of BCNU with surgically implanted bioerodible polymers: a quantitative autoradiographic study. Proc Am Soc Clin Oncol 7: 84, 1988 (Abstract) Grossman SA, Rienhard CS, Brem H, et al: The intracerebral delivery of BCNU with surgically implanted bioerodible polymers: a quantitative autoradiographic study. Proc Am Soc Clin Oncol 7:84, 1988 (Abstract) )| false
Harbaugh RE, , Saunders RL, & Reeder RF: Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 23:693–698, 1988 Harbaugh RE, Saunders RL, Reeder RF: Use of implantable pumps for central nervous system drug infusions to treat neurological disease. **Neurosurgery 23:**693–698, 1988
PubMed Harbaugh RE, Saunders RL, Reeder RF: Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 23: 693– 698, 1988 Harbaugh RE, Saunders RL, Reeder RF: Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 23:693–698, 1988 10.1227/00006123-198812000-00001 )| false
Harsh GR IV, , Levin VA, & Gutin PH, et al: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615–621, 1987 Harsh GR IV, Levin VA, Gutin PH, et al: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. **Neurosurgery 21:**615–621, 1987
PubMed Harsh GR IV, Levin VA, Gutin PH, et al: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615– 621, 1987 Harsh GR IV, Levin VA, Gutin PH, et al: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615–621, 1987 10.1227/00006123-198711000-00002 )| false
Hochberg FH, & Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911, 1980 Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. **Neurology 30:**907–911, 1980
Hochberg FH, , Pruitt AA, & Beck DO, et al: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 63:876–880, 1985 Hochberg FH, Pruitt AA, Beck DO, et al: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. **J Neurosurg 63:**876–880, 1985
PubMed Hochberg FH, Pruitt AA, Beck DO, et al: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 63: 876– 880, 1985 Hochberg FH, Pruitt AA, Beck DO, et al: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 63:876–880, 1985 10.3171/jns.1985.63.6.0876 )| false
Kumar PP, , Good RR, & Jones EO, et al: Contrast-enhancing computed tomography ring in glioblastoma after intraoperative endocurietherapy. Cancer 61:1759–1765, 1988 Kumar PP, Good RR, Jones EO, et al: Contrast-enhancing computed tomography ring in glioblastoma after intraoperative endocurietherapy. **Cancer 61:**1759–1765, 1988
PubMed Kumar PP, Good RR, Jones EO, et al: Contrast-enhancing computed tomography ring in glioblastoma after intraoperative endocurietherapy. Cancer 61: 1759– 1765, 1988 Kumar PP, Good RR, Jones EO, et al: Contrast-enhancing computed tomography ring in glioblastoma after intraoperative endocurietherapy. Cancer 61:1759–1765, 1988 10.1002/1097-0142(19880501)61:9<1759::AID-CNCR2820610907>3.0.CO;2-6 )| false
Leong KW, , Brott BC, & Langer R: Bioerodible polyanhydrides as drug-carrier matrices. I. Characterization, degradation and release characteristics. J Biomed Mat Res 19:941–955, 1985 Leong KW, Brott BC, Langer R: Bioerodible polyanhydrides as drug-carrier matrices. I. Characterization, degradation and release characteristics. **J Biomed Mat Res 19:**941–955, 1985
Leong KW, , D'Amore P, & Marietta M, et al: Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mat Res 20:51–64, 1986 Leong KW, D'Amore P, Marietta M, et al: Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. **J Biomed Mat Res 20:**51–64, 1986
PubMed Leong KW, D'Amore P, Marietta M, et al: Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mat Res 20: 51– 64, 1986 Leong KW, D'Amore P, Marietta M, et al: Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mat Res 20:51–64, 1986 10.1002/jbm.820200106 )| false
Loo TL, , Dion RL, & Sixon RL, et al: The antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 55:492–497, 1966 Loo TL, Dion RL, Sixon RL, et al: The antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea. **J Pharm Sci 55:**492–497, 1966
PubMed Loo TL, Dion RL, Sixon RL, et al: The antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 55: 492– 497, 1966 Loo TL, Dion RL, Sixon RL, et al: The antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 55:492–497, 1966 10.1002/jps.2600550509 )| false
Mathiowitz E, & Langer R: Polyanhydride microspheres as drug carriers. J Controlled Release 5:13–22, 1987 Mathiowitz E, Langer R: Polyanhydride microspheres as drug carriers. **J Controlled Release 5:**13–22, 1987
Mathiowitz E, , Saltzman M, & Domb A, et al: Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J Appl Polymer Sci 35:755–774, 1988 Mathiowitz E, Saltzman M, Domb A, et al: Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. **J Appl Polymer Sci 35:**755–774, 1988
PubMed Mathiowitz E, Saltzman M, Domb A, et al: Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J Appl Polymer Sci 35: 755– 774, 1988 Mathiowitz E, Saltzman M, Domb A, et al: Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J Appl Polymer Sci 35:755–774, 1988 10.1002/app.1988.070350316 )| false
Mcbiddle EK, , Selby PJ, & Perren TJ, et al: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58:779–782, 1988 Mcbiddle EK, Selby PJ, Perren TJ, et al: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. **Br J Cancer 58:**779–782, 1988
PubMed Mcbiddle EK, Selby PJ, Perren TJ, et al: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58: 779– 782, 1988 Mcbiddle EK, Selby PJ, Perren TJ, et al: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58:779–782, 1988 10.1038/bjc.1988.308 )| false
Neuwelt EA, , Howieson J, & Frenkel EP, et al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhanced by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573–582, 1986 Neuwelt EA, Howieson J, Frenkel EP, et al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhanced by blood-brain barrier modification in glioblastoma. **Neurosurgery 19:**573–582, 1986
PubMed Neuwelt EA, Howieson J, Frenkel EP, et al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhanced by blood-brain barrier modification in glioblastoma. Neurosurgery 19: 573– 582, 1986 Neuwelt EA, Howieson J, Frenkel EP, et al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhanced by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573–582, 1986 10.1227/00006123-198610000-00011 )| false
Penta JS, , Rosencweiz M, & Guarino AM, et al: Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3:97–101, 1979 Penta JS, Rosencweiz M, Guarino AM, et al: Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for Phase I clinical trials. **Cancer Chemother Pharmacol 3:**97–101, 1979
PubMed Penta JS, Rosencweiz M, Guarino AM, et al: Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3: 97– 101, 1979 Penta JS, Rosencweiz M, Guarino AM, et al: Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3:97–101, 1979 )| false
Tamargo RJ, , Epstein JI, & Reinhard CS, et al: Brain biocompatibility of a biodegradable controlled release polymer in rats. J Biomed Mat Res 23:253–266, 1989 Tamargo RJ, Epstein JI, Reinhard CS, et al: Brain biocompatibility of a biodegradable controlled release polymer in rats. **J Biomed Mat Res 23:**253–266, 1989
PubMed Tamargo RJ, Epstein JI, Reinhard CS, et al: Brain biocompatibility of a biodegradable controlled release polymer in rats. J Biomed Mat Res 23: 253– 266, 1989 Tamargo RJ, Epstein JI, Reinhard CS, et al: Brain biocompatibility of a biodegradable controlled release polymer in rats. J Biomed Mat Res 23:253–266, 1989 10.1002/jbm.820230209 )| false
Wolpert SM, , Swan ES, & Heros D, et al: Selective delivery of chemotherapeutic agents with a new catheter system. Radiology 166:547–549, 1988 Wolpert SM, Swan ES, Heros D, et al: Selective delivery of chemotherapeutic agents with a new catheter system. **Radiology 166:**547–549, 1988
PubMed Wolpert SM, Swan ES, Heros D, et al: Selective delivery of chemotherapeutic agents with a new catheter system. Radiology 166: 547– 549, 1988 Wolpert SM, Swan ES, Heros D, et al: Selective delivery of chemotherapeutic agents with a new catheter system. Radiology 166:547–549, 1988 10.1148/radiology.166.2.3336733 )| false
Yang MB, , Tamargo RJ, & Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49:5103–5107, 1989 Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. **Cancer Res 49:**5103–5107, 1989
PubMed Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49: 5103– 5107, 1989 Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 49:5103–5107, 1989 )| false